Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 82009-021

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 82009-021). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container (Container)

Each tablet contains 97 875 mg of clopidogrel bisuifate USP equivalent 0 75 mg of clopidogrel base. The usual adult dosage information is not available. It is recommended to preserve in well-closed containers and store at 20°C-25°C (68°F-1077°F) [See USP Controlled Room Temperature]. The medicine is available in tablet form with NDC 82009-021-90, and it is advised for the pharmacist to dispense the medication guide to each patient. For more information, please visit www.quallentpharmaceuticals.com. The rest of the text seems to be a label with a lot number, expiration date, and a barcode.*

FDA Label Image

Figure1 (Figure1)

This appears to be a table or a graph that shows the effect of co-administered PPI on the active metabolite AUC (area under the curve) for different doses and types of medication. However, without further information or better quality text, it is difficult to interpret the data.*

FDA Label Image

Figure2 (Figure2)

The text appears to be a chart or graph displaying data related to the use of Placebo (+ aspirin) and Clopidogrel + aspirin in relation to cumulative event rate over a period of several months of follow-up. Without further context or information it is difficult to provide a more detailed description.*

FDA Label Image

Figure3 (Figure3)

FDA Label Image

Figure4 (Figure4)

The text seems to be presenting results of a trial comparing the effects of Placebo and Clopidogrel on mortality rates. The trial included subjects who were followed for up to 28 days, and the observed mortality rate in the Clopidogrel group was lower than in the Placebo group, with a proportional risk reduction of 7% (significant at p=0.03). However, the output contains some jumbled characters and misspelled words, making some parts of the text unclear.*

FDA Label Image

Figure5 (Figure5)

This appears to be a summary of a clinical trial evaluating the effectiveness of clopidogrel versus a placebo in reducing the risk of death, reinfarction, or stroke before first discharge. The trial involved over 2000 participants and found that clopidogrel resulted in a 9% reduction in risk compared to the placebo, with a significance level of p=0.002. The number of events in the clopidogrel group was not provided in the given text.*

FDA Label Image

Figure6 (Figure6)

FDA Label Image

Figure7 (Figure7)

This is a description of a medical event rate related to vascular health, both fatal and non-fatal. Clopidogrel is mentioned as a possible treatment or preventative measure.*

FDA Label Image

Figure8 (Figure8)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.